Please refer to our Financial Services Guide (FSG) for more information at
Although consumables revenue is expected to be sustained for the life span of trophon thereafter, which stands at eight years, ultimately this too is at risk.”Nanosonics was founded in 2001 and listed on the ASX in 2007 at about 77 cents. FactSet (a) does not make any express or implied warranties of any kind regarding the data, including, without limitation, any warranty of merchantability or fitness for a particular purpose or use; and (b) shall not be liable for any errors, incompleteness, interruption or delay, action taken in reliance on any data, or for any damages resulting therefrom. Developing markets, however, will be tougher nut to crack.Nanosonics has a sound balance sheet and cash flow but Quinn does not expect it to pay a dividend for the foreseeable future.“The company first posted a profit in fiscal 2016 and has not yet paid a dividend, nor do we expect it to in the near future as it invests in bringing its new product to market.“However, the company is free cash flow positive and we forecast it to convert close to 100 per cent of net income into free cash flow in a typical year.”Any Morningstar ratings/recommendations contained in this report are based on the full research report available from Morningstar.© 2020 Morningstar, Inc. All rights reserved.
NAN.AU updated stock price target summary. Nanosonics, which pioneered the high-level disinfectant (HDL) trophon device, has about 20 per cent global market share. In 2013 Michael Kavanagh was appointed CEO of Nanosonics Limited ().This report will, first, examine the CEO compensation levels in comparison to CEO compensation at … Nanosonics (ASX: NAN) is more than 130 per cent overvalued according to the $2.95 fair value estimate of Morningstar analyst Nicolette Quinn. This information is to be used for personal, non-commercial purposes only. Morningstar has begun coverage of Nanosonics, the market leader in infection prevention for medical devices such as ultrasounds, awarding it a narrow moat but raising concerns about the potential for a copycat product to undercut its flagship trophon device.Nanosonics, which pioneered the high-level disinfectant (HDL) trophon device, has about 20 per cent global market share. We will use the Discounted Cash Flow (DCF) model on this occasion. Nanosonics Ltd. Its products include trophon EPR, trophon technology, and trophon2 The company was founded by Maurie Stang on November 14, 2000 and is … 2020
While the trophon device patent only extends to 2025, Quinn says the revenue stream generated by consumables will last beyond a decade.Quinn has excluded an expansion of the product into China, citing a lack of clinical support, but she expects it to be successful in Japan.
Nanosonics Limited engages in the research, development, and commercialization of infection control and decontamination products, and related technologies in Australia and … Data may be intentionally delayed pursuant to supplier requirements.
She expects its 50 per cent market share in the US to reach 80 per cent by the end of the decade. It has installed about 20,000 trophon units in an addressable market of about 120,000. Any general advice or 'class service' have been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. Nanosonics Ltd. analyst ratings, historical stock prices, earnings estimates & actuals. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Nanosonics Ltd (NAN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. High-level disinfection of probes is traditionally done manually by soaking them in chemicals. Nanosonics Reports NPAT Down 19.62% to $5.71m for the Half-Year to 31 December 2019: 03 Apr 2020 Nanosonics Provides Business Update: 26 Feb 2020 Nanosonics Provides 2020 Half Year Financial Results: 26 Feb 2020 Nanosonics Announces 2020 Half-Year Financial Results Morningstar, Inc. All rights reserved.